| Summary of Segment Profit or Loss, Including Significant Expenses |
The table below is a summary of the segment profit or loss, including significant expenses, in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
|
|
2026 |
|
|
2025 |
|
2026 |
|
|
2025 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
Product revenue, net |
$ |
9,122 |
|
|
$ |
— |
|
$ |
14,888 |
|
|
$ |
— |
|
Collaboration revenue |
|
11,752 |
|
|
|
15,288 |
|
|
24,251 |
|
|
|
29,396 |
|
Total revenue |
|
20,874 |
|
|
|
15,288 |
|
|
39,139 |
|
|
|
29,396 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
Cost of product sales |
|
243 |
|
|
|
— |
|
|
505 |
|
|
|
— |
|
Ziftomenib-related costs |
|
34,938 |
|
|
|
37,584 |
|
|
71,818 |
|
|
|
67,531 |
|
Darlifarnib-related costs |
|
5,985 |
|
|
|
6,141 |
|
|
12,553 |
|
|
|
11,376 |
|
Discovery stage program-related costs |
|
1,901 |
|
|
|
1,490 |
|
|
3,301 |
|
|
|
3,579 |
|
Research and development personnel costs and other expenses |
|
15,829 |
|
|
|
14,856 |
|
|
33,029 |
|
|
|
30,231 |
|
Share-based compensation expense |
|
8,209 |
|
|
|
6,949 |
|
|
16,625 |
|
|
|
14,791 |
|
Other segment expenses(1) |
|
26,779 |
|
|
|
20,934 |
|
|
53,133 |
|
|
|
39,254 |
|
Total operating expenses |
|
93,884 |
|
|
|
87,954 |
|
|
190,964 |
|
|
|
166,762 |
|
Other income (expenses) |
|
|
|
|
|
|
|
|
|
|
Interest and other income, net |
|
5,033 |
|
|
|
6,935 |
|
|
10,859 |
|
|
|
14,814 |
|
Interest expense |
|
(345 |
) |
|
|
(391 |
) |
|
(681 |
) |
|
|
(773 |
) |
Income tax expense |
|
(5 |
) |
|
|
— |
|
|
(13 |
) |
|
|
(226 |
) |
Segment and net loss |
$ |
(68,327 |
) |
|
$ |
(66,122 |
) |
$ |
(141,660 |
) |
|
$ |
(123,551 |
) |
(1)Other segment expenses are comprised of selling, general and administrative expenses, excluding share-based compensation expense, which is shown separately.
|